A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
Key facts
- Who runs it
- Cinclus Pharma Holding AB
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 121 people, planned
- Started
- 13 Jul 2022
- Expected to end
- 30 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Linaprazan glurate
- Placebo
- Record updated
- 17 June 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Main inclusion Criteria:
- Willing and able to give written informed consent for participation in the study
- Healthy male or female aged 18 to 65 years
- Body mass index ≥18.5 and ≤35.0 kg/m2
- Prospective subjects, as well as their partners, must agree to contraception requirements; Main exclusion criteria:
- Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of <1%) from 2 weeks prior to dosing until the end-of-study visit
- Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocol
- History of or current clinically significant disease as defined in the protocol
- History of GERD, significant acid reflux
- Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol/L).
The 2 groups in the trial
- Linaprazan glurateTreatment being tested
Oral administration as a single dose of 300 mg, 600 mg, 150 mg, 275 mg, and up to 2 additional dose levels.
- PlaceboPlacebo, for comparison
Oral administration as a singel dose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase I Trial to Investigate the Pharmacokinetics and ECG Effects of Single Doses of Linaprazan Glurate Administered as Oral Tablets to Healthy Participants
- Criteria questions
- Built from NCT05469854, who can take part
- Record updated
- 17 June 2026